AVENUE THERAPEUTICS INC (ATXI) Fundamental Analysis & Valuation
NASDAQ:ATXI • US05360L4032
Current stock price
0.42 USD
-0.43 (-50.71%)
At close:
0.3998 USD
-0.02 (-4.81%)
After Hours:
This ATXI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. ATXI Profitability Analysis
1.1 Basic Checks
- In the past year ATXI has reported negative net income.
- In the past year ATXI has reported a negative cash flow from operations.
- In the past 5 years ATXI always reported negative net income.
- ATXI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of ATXI (-360.69%) is worse than 91.84% of its industry peers.
- ATXI has a Return On Equity of -362.76%. This is in the lower half of the industry: ATXI underperforms 76.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -360.69% | ||
| ROE | -362.76% | ||
| ROIC | N/A |
ROA(3y)-235.68%
ROA(5y)-231.27%
ROE(3y)-285%
ROE(5y)-290.87%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for ATXI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. ATXI Health Analysis
2.1 Basic Checks
- Compared to 1 year ago, ATXI has more shares outstanding
- ATXI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- ATXI has an Altman-Z score of -35.88. This is a bad value and indicates that ATXI is not financially healthy and even has some risk of bankruptcy.
- ATXI has a Altman-Z score of -35.88. This is amonst the worse of the industry: ATXI underperforms 89.80% of its industry peers.
- ATXI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -35.88 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 2.70 indicates that ATXI has no problem at all paying its short term obligations.
- ATXI's Current ratio of 2.70 is in line compared to the rest of the industry. ATXI outperforms 48.98% of its industry peers.
- A Quick Ratio of 2.70 indicates that ATXI has no problem at all paying its short term obligations.
- The Quick ratio of ATXI (2.70) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.7 | ||
| Quick Ratio | 2.7 |
3. ATXI Growth Analysis
3.1 Past
- ATXI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.44%, which is quite impressive.
EPS 1Y (TTM)83.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-142.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 25.69% on average over the next years. This is a very strong growth
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y95.15%
EPS Next 2Y40.88%
EPS Next 3Y25.69%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. ATXI Valuation Analysis
4.1 Price/Earnings Ratio
- ATXI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year ATXI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as ATXI's earnings are expected to grow with 25.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.88%
EPS Next 3Y25.69%
5. ATXI Dividend Analysis
5.1 Amount
- ATXI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ATXI Fundamentals: All Metrics, Ratios and Statistics
0.42
-0.43 (-50.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength65.84
Industry Growth15.53
Earnings (Last)03-30 2026-03-30/amc
Earnings (Next)N/A N/A
Inst Owners10.54%
Inst Owner Change0%
Ins Owners13.22%
Ins Owner Change3.83%
Market Cap802.20K
Revenue(TTM)N/A
Net Income(TTM)-9.47M
Analysts82.86
Price Target8.16 (1842.86%)
Short Float %0.19%
Short Ratio0.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-300.31%
Min EPS beat(2)-500.37%
Max EPS beat(2)-100.25%
EPS beat(4)1
Avg EPS beat(4)-127.39%
Min EPS beat(4)-500.37%
Max EPS beat(4)158.82%
EPS beat(8)3
Avg EPS beat(8)-138.86%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-33.33%
PT rev (3m)-33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)43%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.31 | ||
| P/tB | 0.31 | ||
| EV/EBITDA | N/A |
EPS(TTM)-19.25
EYN/A
EPS(NY)-2
Fwd EYN/A
FCF(TTM)-5.54
FCFYN/A
OCF(TTM)-5.54
OCFYN/A
SpS0
BVpS1.37
TBVpS1.37
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -360.69% | ||
| ROE | -362.76% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-235.68%
ROA(5y)-231.27%
ROE(3y)-285%
ROE(5y)-290.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.7 | ||
| Quick Ratio | 2.7 | ||
| Altman-Z | -35.88 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-142.67%
EPS Next Y95.15%
EPS Next 2Y40.88%
EPS Next 3Y25.69%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-128.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-128.64%
OCF growth 3YN/A
OCF growth 5YN/A
AVENUE THERAPEUTICS INC / ATXI Fundamental Analysis FAQ
What is the ChartMill fundamental rating of AVENUE THERAPEUTICS INC (ATXI) stock?
ChartMill assigns a fundamental rating of 2 / 10 to ATXI.
Can you provide the valuation status for AVENUE THERAPEUTICS INC?
ChartMill assigns a valuation rating of 1 / 10 to AVENUE THERAPEUTICS INC (ATXI). This can be considered as Overvalued.
How profitable is AVENUE THERAPEUTICS INC (ATXI) stock?
AVENUE THERAPEUTICS INC (ATXI) has a profitability rating of 0 / 10.
What is the expected EPS growth for AVENUE THERAPEUTICS INC (ATXI) stock?
The Earnings per Share (EPS) of AVENUE THERAPEUTICS INC (ATXI) is expected to grow by 95.15% in the next year.